Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Made from high-quality, pharmaceutical-grade ingredients
Ayse Levent, SVP, Ipsos Global Healthcare Monitors Drug: Retatrutide Company: Eli Lilly Indication: Obesity, cardiovascular and metabolic disease Stage: Phase III Background: Retatrutide is a first-in-class GIP/GLP-1/glucagon triagonist combining GLP-1, GIP and glucagon activity to reduce appetite, improve glucose metabolism and increase energy expenditure
The researchers concluded that AOD9604 displayed a very good safety and tolerability profile indistinguishable from placebo. Critically, zero serious adverse events were attributed to the peptide, and no participants withdrew due to treatment-related effects
Active Ingredient: Delta Sleep-Inducing Peptide (DSIP) 5 mg Inactive Ingredients: Lyophilized powder without preservatives DSIP Vials: Quantity based on selected package (1, 4, or 10 vials of 5 mg each) Antibacterial Water: Equal number of 2 ml vials for reconstitution Test Certificate: Included to confirm product purity and quality DSIP 5 out of 5 based on 1 customer rating USD $42.99 USD $42.99 USD $42.99 sample DSIP-5 is a research-grade nonapeptide offered at 5 mg per vial as a lyophilized powder
US$ 21.30
US$ 21.00
US$ 27.36
US$ 25.82
US$ 21.86
